Abstract:OBJECTIVE:To explore the clinical characteristics, therapeutic and clinical significance for RET proto-oncogene screening in a pedigree with familial medullary thyroid carcinoma.METHODS:Comprehensive medical history was obtained from 19 members in a 4-generate southern Chinese family. Systemic clinical investigations including biochemical testing, imaging examinations and germline RET screening.RESULTS:RET screening showed heterozygous missense mutations of TGC to TAC at codon 618 on exon 10 in 8 cases (p.C618Y) completely consistent with the clinical manifestations. The clinical data of 7 patients with medullary thyroid carcinoma (MTC) and 2 carriers of asymptomatic RET mutation from were analyzed. Single/bilateral multi-centric MTC with lymph node metastases was confirmed in 6 cases by histopathology and 1 case by clinical examination. There were 1 male and 6 females with an initial mean diagnostic age was 49.6 years (range: 24 - 78). All had palpable neck masses. And the mean maximum diameter of MTC was 2.6 cm (range 1.4 - 4.4). Seven patients underwent thyroidectomy except a 78-year-old female patient: right total and left subtotal thyroidectomy (n = 1), right total thyroidectomy (previous left total thyroidectomy for benign mass) (n = 1) and total thyroidectomy (n = 4) were performed. All procedures were accompanied by at least bilateral level VI lymph node dissection and/or with modified single/bilateral neck dissection. After the first operation, 6 patients still presented a high value of calcitonin: 1 patient died of metastasis 64 months postoperatively; 3 patients underwent reoperation at 6 months after initial operation, the calcitonin levels dropped to normal in 2/3 cases and stayed higher in 1 case; another two cases presented bilateral thyroid gland residua, local lymph node enlargement on imaging examination and elevated levels of calcitonin at 214 and 60 months postoperation respectively. However, 1/2 asymptomatic with elevated pre-operative calcitonin subjects underwent total thyroidectomy and histopathological examination showed bilateral C cell hyperplasia. The other carriers, without surgery, with normal neck images, close monitoring and a 10-month follow-up, still presented undetectable calcitonin.CONCLUSIONS:Based on family survey, integrated RET screening and serum levels of calcitonin facilitate an early diagnosis and normalize surgery to improve the prognosis. For asymptomatic RET mutation carriers, their levels of calcitonin shall guide the individualized regimen of prophylactic thyroidectomy or strict monitoring and follow-ups.

C634Y mutation in RET -induced multiple endocrine neoplasia type 2A: A case report

RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Multiple Endocrine Neoplasia Type 2A Caused by a P.c618r RET Proto-Oncogene Mutation in a Chinese Pedigree

Multiple Endocrine Neoplasia 2A with RET Mutation P.cys611tyr: A Case Report.

The Trends in Early Precision Diagnosis and Treatment Strategies of Multiple Endocrine Neoplasia Type 2

Preimplantation Genetic Diagnosis of Multiple Endocrine Neoplasia Type 2A Using Informative Markers Identified by Targeted Sequencing.

RET Germline Mutations Identified by Exome Sequencing in a Chinese Multiple Endocrine Neoplasia Type 2a/familial Medullary Thyroid Carcinoma Family.

Ret Proto-Oncogene Mutations Are Restricted To Codons 634 And 918 In Mainland Chinese Families With Men2a And Men2b

The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees]

Screening of RET Gene Mutations in Chinese Patients with Medullary Thyroid Carcinoma and Their Relatives

MEN2 phenotype in a family with germline heterozygous rare RET K666N variant

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma

RET Proto-Oncogene Genetic Screening of Families with Multiple Endocrine Neoplasia Type 2 Optimizes Diagnostic and Clinical Management in China.

Mutation of the ret proto-oncogene in two Chinese families with multiple endocrine neoplasia type 2A(MEN2A).

The clinical features of multiple endocrine neoplasia type 2A (MEN2A)and ret proto-oncogene mutation study

[Clinical Diagnosis and Treatment of Familial Medullary Thyroid Carcinoma Caused by a P.c618y RET Proto-Oncogene Mutation in a Chinese Pedigree].

RET 634 germline/gonadal mosaicism generating a second pathogenic amino acid change in multiple endocrine neoplasia type 2A

Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma

[Genotype-phenotype correlations in multiple endocrine neoplasia type 2]

[Mutation of the RET proto-oncogene in type 2A multiple endocrine neoplasia Chinese families and the application of pentagastrin stimulation test in diagnosis and follow-up].